How To Avoid Common Pitfalls In Preclinical Development

By Gary Watts, Head of Formulation Development

Early preclinical decisions set the trajectory for development success, yet many programs stumble on avoidable issues. Common pitfalls include weak target validation, late recognition of developability risks, misaligned study designs, and fragmented handoffs between discovery, CMC, and toxicology. These gaps often lead to rework, budget overruns, and delays entering the clinic.

A more resilient approach emphasizes early, cross‑functional planning anchored in the intended clinical profile. Evaluating manufacturability, stability, and bioanalytical readiness alongside pharmacology and safety helps surface risks while they are still manageable. Thoughtful model selection, fit‑for‑purpose assays, and clear decision criteria strengthen data quality and confidence. Equally important is building realistic timelines and governance structures that support informed go/no‑go decisions.

By integrating scientific rigor with practical development considerations from the outset, teams can reduce uncertainty, protect investment, and move promising candidates forward with greater speed and confidence across organizations, portfolios, and therapeutic modalities in complex preclinical pipelines today worldwide.